---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-113763"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2026-10-05T21:00:54+00:00"
generated_at: "2026-10-12T14:57:11.980048+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Iovance raises FY2026 revenue guidance to $410M–$420M, ~15% above prior range at midpoint

## Summary
- FY2026 revenue guidance raised to $410M–$420M; midpoint is $55M (~15%) above prior $350M–$370M range.
- 2Q26 revenue exceeded guidance by more than 10%; ~$304M cash as of June 30, 2026 supports runway into 2H28.
- ~100 authorized treatment centers as of Oct 5, 2026; ~2,000 patients treated with commercial and clinical Iovance TIL products.
- 5-year Amtagvi data: 31.4% ORR, 19.7% OS, mDOR 36.5 months; real-world ORR ~44% and 52% in patients with ≤2 prior lines.
- TILVANCE-301 Phase 3 frontline melanoma trial (N=670, 80+ sites) enrolls on track; IOV-LUN-202 NSCLC showed 25.6% ORR.

## SEC filing metadata
- accession: 0001104659-26-113763
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2026-10-05T21:00:54+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465926113763/0001104659-26-113763-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465926113763/tm2627047d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-113763
- JSON: https://secwatch.observer/filing/0001104659-26-113763.json
- Plain text: https://secwatch.observer/filing/0001104659-26-113763.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.